共 50 条
- [44] Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
- [45] Successful Combination Therapy of BRAF- and MEK-Inhibitor after Progress under BRAF-Inhibitor Mono Therapy: Report of a Patient with brain metastatic Melanoma JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 166 - 166
- [48] Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F ANNALS OF ONCOLOGY, 2021, 32 : S669 - S670
- [49] A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib plus pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass). JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 523 - 523
- [50] First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma A randomized, double-blind Phase-3-Study Comparing the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab and Placebo as First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma who are not suitable for a Cisplatin-based Therapy and whose Tumors express PD-L1, as well as for Patients who are not suitable for a platinum-based Therapy regardless of the PD-L1-Expression (LEAP-011-AB 68/18 of the AUO) AKTUELLE UROLOGIE, 2021, 52 (01) : 28 - 29